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OBJECTIVES: We assessed the safety, efﬁcacy, and tolerability of a new preparation of Gatorade and polyethylene glycol (PEG)
for colonoscopy with or without bisacodyl compared with NuLYTELY.
METHODS: We performed an investigator-blinded, placebo-controlled, randomized trial of 64oz of Gatorade and 306g of PEG
(G/PEG) with or without 10mg of bisacodyl and NuLYTELY. A total of 600 outpatients consumed their preparation the day before
a morning colonoscopy. The primary endpoint was colon cleanliness assessed by the Boston Bowel Preparation Scale (BBPS).
Tolerability was assessed using a subject questionnaire, and safety was assessed from a basic metabolic proﬁle drawn before
the colonoscopy.
RESULTS: Adding bisacodyl to G/PEG caused more abdominal bloating/cramps (Po0.01) and did not result in a cleaner colon
(P¼0.66) compared with G/PEG without bisacodyl. The BBPS scores in both the G/PEG arms and NuLYTELY arm were not
signiﬁcantly different (P¼0.19). Compared with subjects in the NuLYTELY arm, subjects in the G/PEG without bisacodyl arm
had less nausea (Po0.04), vomiting (Po0.02), abdominal pain (Po0.02), bloating (Po0.005), difﬁculty drinking the liquid
(Po0.0001), and found the overall preparation easier to tolerate (Po0.0001). Subjects in the combined G/PEG arms had a lower
serum sodium (Po0.0007), chloride (Po0.007), and BUN (Po0.0001) levels than those in the NuLYTELY arm, but this did not
cause any clinical symptoms.
CONCLUSIONS: Bisacodyl added to G/PEG for colon lavage caused more side effects and did not result in a cleaner colon.
The G/PEG preparations cleansed the colon as well as NuLYTELY, were far better tolerated, and were equally safe.
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INTRODUCTION
Colon cancer was the second leading cause of cancer death
in the United States in 2008 (http://seer.cancer.gov/faststat).
Colonoscopy is probably the most effective screening method
for colon cancer, but in 2008, only 53.0–58.5% of the US
population aged 50–75 years had undergone a colonoscopy
in the past 10 years.
1 Concern about the bowel preparation
was the most common reason cited by people older than age
50 years for not having a colonoscopy.
2
Over the past few decades, attempts have been made to
improve the tolerability and efﬁcacy of the bowel preparations
used for colonoscopy (see Table 1).
Four-liter polyethylene glycol 3,350 and electrolyte solutions
(PEG-ELS)
3arenotalwayswelltoleratedbypatients(GoLYTELY,
Braintree Laboratories, Braintree, MA, USA; CoLyte, Alaven
Pharmaceutical, LLC, Marietta, GA, USA).
4 Sulfate-free
versions of PEG-ELS (SF-PEG-ELS)
5 are only minimally
better tolerated by patients (NuLYTELY, Braintree Labora-
tories; TriLyte, UCB, Brussels, Belgium).
4 Safety concerns
6,7
have limited the use of sodium phosphate preparations
8
(VISICOL and OsmoPrep, Salix Pharmaceuticals, Raleigh,
NC, USA).
Bisacodyl, a poorly absorbed diphenylmethane laxative
thatstimulates peristalsis, has been used with a 2-liter version
of SF-PEG-ELS (HalfLytely, Braintree Laboratories), but
there is no evidence that bisacodyl is effective.
4
Combinations of PEG (MiraLAX, Merck, Whitehouse
Station, NJ, USA) in low ELS (e.g., Gatorade, The Gatorade
Company, Chicago, IL, USA) and bisacodyl have been
used in an attempt to improve the tolerability of the bowel
preparation. Two investigator-blinded trials
9,10 of 238–255g
PEG in 64oz of Gatorade and 10–20mg bisacodyl com-
paredwitha4-literPEG-ELSfoundbetterqualitypreparations
with the PEG-ELS and only a minimal difference in toler-
ability.
Our uncontrolled observations with 238g of PEG and 64oz
of Gatorade with or without 10–20mg of bisacodyl were
disappointing, with an unacceptably high number of sub-
optimal colonoscopy preparations, and patients complained
thatthe 306g ofPEG (G/PEG) preparationtook longer tostart
working and kept them up at night.
We modiﬁed our protocol by increasing the PEG to 306g
given the day before the colonoscopy as 51g at noon
and 255g from 1700 to 2100h with 64oz of Gatorade, and
eliminated the bisacodyl. Our uncontrolled observations
with the modiﬁed G/PEG protocol showed the quality of the
preparations were similar to those with NuLYTELY. Patients
seemed to tolerate the G/PEG preparation better than the
commercial PEG preparations.
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www.nature.com/ctgThe objective of this study was to evaluate the safety,
efﬁcacy, and tolerability of a G/PEG preparation with or
without 10mg of bisacodyl compared with a preparation with
NuLYTELY (or TriLyte). The study used an investigator-
blinded, placebo-controlled, randomized trial format to com-
pare the three preparations.
METHODS
Study design and oversight. The protocol was approved
by the Adventist Midwest Region Institutional Review
Board (AMH 2010-01-80, ClinicalTrials.gov NCT01063049).
The trial was designed by the authors with no outside input.
Adventist Hinsdale Hospital donated 171 basic meta-
bolic proﬁles (BMPs) and waived the fee for the Institu-
tional Review Board. All other expenses associated with this
study were paid for by the authors. Subjects received no
ﬁnancial reward and paid for their preparations.
The study was an investigator-blinded, placebo-controlled,
randomized trial of three bowel preparations as follows: (1)
NU: NuLYTELY (or TriLyte) 4-liter (1 gallon) consumed from
1700 to 2100h the night before the colonoscopy; (2) G/
PEGþP: PEG 51g in 355ml (12oz) of any clear liquid and a
placebo (two 0.4mg folic acid tablets) consumed at noon the
day before the colonoscopy and PEG 255g in Gatorade
1,872ml (half gallon, 64oz) consumed from 1700 to 2100h
the day before the colonoscopy; and (3) G/PEGþB: PEG
51g in 355ml (12oz) of any clear liquid and bisacodyl (two
5mg tablets, Major Pharmaceuticals, Livonia, MI, USA)
consumed at noon the day before the colonoscopy and PEG
255ginGatorade1,872mlconsumedfrom1700to2100hthe
day before the colonoscopy. Subjects in the Gatorade arms
were blinded to the inclusion of bisacodyl or placebo tablets,
and were allowed to choose any non-red variety of Gatorade.
Subjects were on clear liquids the day before the colonoscopy
and instructed to consume nothing by mouth after midnight,
except for medications taken in the morning. Subjects were
instructed to take Fleets enemas if their stool was not clear on
the morning of the colonoscopy.
Folic acid was chosen as a cost-effective placebo for
bisacodyl, because both tablets were about the same color
and size.
Subjects had their colonoscopy performed between
February 2010 and February 2011 by one of three gastro-
enterologists (DG, JH, and MR) with 17 to 34 years of
experience. Colonoscopies were scheduled to begin between
0800handnooninthegastrointestinallabsatourofﬁceortwo
community hospitals.
Subjectswereoutpatientsundergoingelectivecolonoscopy
and at least 18 years of age. Exclusion criteria included: (1)
allergies or intolerances to any of the study drugs; (2)
pregnancy; (3) those who required a multiple-day colon
preparation for previous colonoscopies; or (4) those with
ileus, gastrointestinal obstruction, gastric retention, bowel
perforation, toxic colitis, or toxic megacolon. Each subject
signed an informed consent document.
Beforethestudybegan,itwasdeterminedthatatotalof600
subjects would be enrolled with 200 subjects in each of the
three bowel preparation arms. Our staffs were trained to
screen and recruit all patients who met the inclusion criteria.
Approximately 1,000 consecutive patients were invited to
participate in the study to recruit the 600 subjects included in
this study. The most common reasons patients declined to
Table 1 Select colon lavage preparations available for sale in the United States
CoLyte or
GoLYTELY
TriLyte or
NuLYTELY
HalfLytely MoviPrep Gatorade+
PEG
VISICOL #32
tablets
SUPREP
Sodium bicarbonate (g) 6.74 5.72 2.86
Sodium chloride (g) 5.86 11.2 5.6 5.38 1.19
Sodium sulfate (g) 22.74 15 35
Sodium citrate (g) 0.68
Sodium phosphate (g) 48
Potasium-H2-phosphate (g) 0.84
Potassium chloride (g) 2.97 1.48 0.74 2.03
Potassium sulfate (g) 6.26
PEG-3350 (g) 236 420 210 200 306
Sodium ascorbate (g) 11.8
Ascorbic acid (g) 9.4
Magnesium sulfate (g) 3.2
Fructose/sucrose (g) 112
Water (ml) 4000 4000 2000 2000 2247 2000 2839
Sodium (mmol) 500 260 130 363.6 38 416 493
Potassium (mmol) 40 20 10 28.4 6 71
Magnesium (mmol) 27
Chloride (mmol) 140 212 106 119.6 20
Bicarbonate (mmol) 80 68 34
Sulfate (mmol) 160 105.6 308
Phosphate (mmol) 6 326
Ascorbate (mmol) 59.6
Citrate (mmol) 6
PEG-3350 (mmol) 70.4 125.2 62.6 59.2 91.2
Cost ($) 16.78 25.32 63.68 64.84 16.56 66.68 80.32
Contentsobtained fromthe packageinserts.Cost dataforpatients paying cashatWal-MartinJanuary2011inIllinois, USA,fortheleast-expensive version(generic if
available).
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Clinical and Translational Gastroenterologyparticipate in the study were that they wanted to choose their
own bowel preparation, and they did not want to have blood
drawn for a BMP. Randomization was performed using a
computer-generated random number table in blocks of 30
subjects with 10 of each of the bowel preparation randomly
distributed within each block. Each subject received an
identical-appearing envelope with bowel-preparation instruc-
tions enclosed (see Supplementary Information (pages 1 and
2 online)). The envelopes for the G/PEG arms of the study
contained two 5mg bisacodyl or 0.4mg folic acid tablets.
Subjects were allowed to withdraw from the study until 24h
before their colonoscopy, and were replaced with another
randomly selected subject who was given the same bowel-
preparation regimen as the subject who withdrew. Beginning
the day before the colonoscopy, all subjects were evaluated
on an intention-to-treat basis, no matter what bowel prepara-
tion they actually used. Subjects could be switched to another
bowel-cleaningregimenchosenbythephysicianoncallifthey
could not tolerate the one assigned to them.
One author (DF) wasresponsible formonitoring thedata for
any adverse outcomes.
Measurements. A questionnaire was ﬁlled out by each
subject immediately before the colonoscopy (see Supple-
mentary Information (page 3 online)). Subjects were asked to
rate their symptoms of nausea, vomiting, abdominal cramps/
pain, and bloating on a scale of 0 to 3 as follows: 0¼none,
1¼mild, 2¼moderate, and 3¼severe. Subjects were asked:
if they had any other problems during their preparation; how
much of the preparation they drank; if they needed to call the
doctor for advice or help; if they needed to change their
assigned preparation, because they could not drink it all; if
they needed to take any Fleet enemas the morning of the
procedure; if they had to wake up in the middle of the night to
have a bowel movement; and if they would want to use the
same preparation again if they needed a future colonoscopy.
Subjects were asked to rate how difﬁcult it was to drink the
liquid, and overall, how difﬁcult the preparation was. Both
questions were answered on a scale of 0 to 3 as follows:
0¼easy, 1¼mildly difﬁcult, 2¼moderately difﬁcult, and
3¼very difﬁcult. Subjects were asked if they had ever had
a colonoscopy before, what preparation they consumed
previously, and how was the study preparation compared
with their previous preparation (i.e., easier, about the same,
or more difﬁcult).
A BMP was obtained before the intravenous line for the
colonoscopywasstarted.Subjectsknowntohaveacreatinine
Z1.30mg/dl had a baseline BMP drawn in the 30 days before
the colonoscopy.
A questionnaire was ﬁlled out by the gastroenterologist
immediately after the colonoscopy (see Supplementary
Information (page 4 online)) rating the cleanliness of the
bowel preparation. The questionnaire included the subject’s
age and race, the site at which the colonoscopy was per-
formed, if the subject had a history of heart failure or renal
insufﬁciency, the indications for the colonoscopy and the
ﬁndings, if the subject had a previous colon resection, and
whether the cecum (or most proximal extent of the remaining
colon) was reached.
The primary endpoint of this study was the cleanliness of
the colon on the Boston Bowel Preparation Scale (BBPS),
11
and a secondary endpoint was the cleanliness of the colon
on the Ottawa Preparation Scale (OPS)
12 as reported by the
gastroenterologist performing the colonoscopy (see Table 2).
For both bowel-preparation scales, any segment of the
colon that had been completely resected or could not be
reached due to difﬁculty advancing the colonoscope was not
rated. Any segment that could not be reached due to more
distal segments being poorly prepared was given the worst
rating on each scale.
A secondary endpoint of the study was the cleanliness of
the colon as rated by the gastroenterologist. A good-quality
colonoscopy was deﬁned as being able to see at least
95% of the mucosa of the visualized colon after washing
and suctioning; otherwise, the preparation was rated as
inadequate.
Before the study began, each participating gastroenterol-
ogist watched a video (media.bmc.org/Media/BostonBowel-
PreparationScale.wmv) as a calibration exercise for both the
BBPS and OPS. During the study, any segments that proved
difﬁcult to rate were discussed among the authors.
Data analysis. Continuous variables were compared using
Student’s t-test (unpaired, two-tailed). Categoric variables
were compared using Pearson’s w
2-test (non-directional);
however, when the observed frequencies were low, Fisher’s
exact test (two-tailed) was used. P-values of less than 0.05
were regarded as statistically signiﬁcant.
When this study was designed, no studies using the BBPS
had been published. Therefore, we based our sample size
on prior studies of preparation quality and tolerability, and
estimated that 600 patients (200 per arm) would have the
Table 2 The BBPS
11 and the OPS
12
BBPS rating for each colon segment
0¼Unprepared colon segment with stool that cannot be cleared
1¼Portion of mucosa in segment seen after cleaning, but other
areas not seen due to retained material
2¼Minor residual material after cleaning, but mucosa of segment
generally well seen
3¼Entire mucosa of segment well seen after washing
BBPS is calculated by adding the ratings of the right, transverse and
left colon segments. The overall BBPS is reported from 0 (very poor)
to 9 (excellent)
OPS rating for each colon segment
4¼Inadequate (solid stool not cleared with washing and
suctioning)
3¼Poor (necessary to wash and suction to obtain a reasonable
view)
2¼Fair (necessary to suction liquid to adequately view segment)
1¼Good (minimal turbid ﬂuid in segment)
0¼Excellent (mucosal detail clearly visible)
OPS rating for the amount of ﬂuid in the whole colon
2¼Lots of ﬂuid
1¼Moderate ﬂuid
0¼Little ﬂuid
OPS is calculated by adding the ratings of the right, transverse/
descending and sigmoid/rectum colon segments, and rating for the
ﬂuid in the whole colon. The overall OPS is reported from 14 (very
poor) to 0 (excellent)
Abbreviations: BBPS, Boston Bowel Preparation Scale; OPS, Ottawa
Preparation Scale.
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post-hoc analysis with a sample size of 200 subjects per arm,
the probability was 80% that the study would detect a
difference between two arms at a two-sided 0.05 signiﬁcance
level, if the true difference between the BBPS of those arms
was 0.28.
RESULTS
Subjects and endoscopic ﬁndings. The baseline charac-
teristics of the 200 subjects in each of the three arms of
the study were generally well balanced and are shown in
Table 3. Six indications or ﬁndings were signiﬁcantly more
common in one arm than the other arm.
A total of 36 subjects (15 NU, 9 G/PEGþP, 12 G/PEGþB)
withdrewatleast24hbeforetheirscheduledcolonoscopyand
were replaced; 3 subjects (1 NU, 1 G/PEGþP, 1 G/PEGþB)
decided not to undergo a colonoscopy; 14 subjects (3 NU,
4 G/PEGþP, 7 G/PEGþB) postponed their colonoscopy
beyond February 2011; 5 subjects (4 NU, 1 G/PEGþB)
wanted a different preparation than they were randomly
assigned; 5 subjects (3 NU, 2 G/PEGþP) did not want to
have their blood drawn; and 9 subjects (4 NU, 2 G/PEGþP,
3 G/PEGþB) withdrew for unstated reasons.
A post-polypectomy bleed in one subject (1 G/PEGþP)
was the only signiﬁcant complication.
Colon polyps (including two colon cancers) were found in
102 of 196 (52.0%) average-risk subjects undergoing a
screening colonoscopy. Colon polyps (including four colon
cancers) were found in 203 of 404 subjects (50.2%, P¼0.68
vs. average risk subjects) undergoing colonoscopy due to
increased risk or active symptoms.
The cecum (or most proximal extent of the remaining colon)
was reached in 593 of 600 (98.8%) subjects. Of the seven
incomplete colonoscopies, six (3 NU, 1 G/PEGþP, 2 G/
PEGþB) were technically difﬁcult, and one (1 G/PEGþB)
had an obstructing sigmoid cancer. There was not a single
subject in whom the cecum could not be reached due to an
inadequate preparation.
Preparation quality and laboratory changes. The clean-
liness data for each arm are shown in Table 4.
The laboratory data for each arm are shown in Table 5.
A total of 10 subjects (5 NU, 3 G/PEGþP, 2 G/PEGþB)
declined to have their blood drawn, or the nurses forgot
Table 3 Data from the questionnaire ﬁlled out by the gastroenterologists immediately after the colonoscopy
1 NuLYTELY
or TriLyte
2 Gatorade/PEG
with placebo
P-value
1 vs. 2
3 Gatorade/PEG with
10mg bisacodyl
P-value
2 vs. 3
P-value
1v s .3
4 Gatorade/PEG
(both arms)
P-value
1v s .4
N 200 200 200 400
Sex ratio (M:F) 119: 81 109: 91 0.31 101: 99 0.42 0.07 210: 190 0.06
MD (Gerard: Raiser: Holden) 100: 57: 43 95: 64: 41 0.75 85: 71: 44 0.60 0.25 180: 135: 85 0.39
Age in years (mean±s.d.) 60.2±13.2 59.7±13.8 0.71 61.3±12.5 0.22 0.39 60.4±13.1 0.86
Race
Caucasian 173 168 0.48 173 0.48 1.00 341 0.68
African American 8 10 0.63 4 0.10 0.24 14 0.76
Hispanic 8 5 0.40 5 1.00 0.40 10 0.31
Other 11 17 0.24 18 0.86 0.18 35 0.16
Procedure
Performed in our ofﬁce 115 113 0.84 123 0.31 0.42 236 0.73
Start time (mean hour±s.d.) 10.2±0.9 10.3±1.0 0.29 10.2±1.0 0.29 1.00 10.3±1.0 0.23
History of heart failure 0 1 1.00 1 1.00 1.00 2 0.55
Baseline creatinine level Z1.30 9 7 0.61 5 0.56 0.28 12 0.35
Previous colon resection 8 9 0.81 10 0.81 0.63 19 0.68
Indications (multiple indications possible)
Screening 70 67 0.75 59 0.39 0.24 126 0.39
History of polyps 41 56 0.08 62 0.51 o0.02 118 o0.05
History of colon cancer 4 6 0.52 8 0.58 0.24 14 0.31
FH colon neoplasia 28 29 0.89 30 0.89 0.78 59 0.81
Rectal bleeding 39 34 0.52 39 0.52 1.00 73 0.71
Anemia 14 11 0.54 6 0.21 0.07 17 0.15
History of IBD 3 3 1.00 10 o0.05 o0.05 13 0.16
Diarrhea 11 6 0.21 6 1.00 0.21 12 0.13
Recent diverticulitis 1 4 0.37 3 1.00 0.62 7 0.28
Abnormal GI X-ray 0 2 0.50 0 0.50 1.00 2 0.55
Change in bowel habits 0 5 0.06 1 0.22 1.00 6 0.19
Findings (multiple ﬁndings possible)
Normal 61 59 0.82 53 0.50 0.37 112 0.52
Colon polyps 99 100 0.92 102 0.84 0.76 202 0.82
Colon cancer 1 2 1.00 3 1.00 0.62 5 0.67
Diverticulosis 78 59 o0.05 61 0.82 0.07 120 o0.03
Crohn’s disease 1 0 1.00 8 o0.008 o0.04 8 0.28
Ulcerative colitis 2 5 0.45 5 1.00 0.45 10 0.35
Other colitis 4 4 1.00 2 0.69 0.69 6 0.74
Incomplete colonoscopy 3 1 0.62 3 0.62 1.00 4 0.69
Abbreviations: M, male; F, female; IBD, inﬂammatory bowel disease; GI, gastrointestinal tract.
P-values in bold signify signiﬁcance levels o0.05.
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subjects (6 NU, 5 G/PEGþP, 3 G/PEGþB) had hemolyzed
samples, making the potassium result unusable. One
subject’s blood (1 NU) was so hemolyzed that all the values
in the BMP were unusable.
Three subjects, all with no known pre-existing renal
disease, had post-preparation serum sodium levels
r130mmol/l (1 NU¼129mmol/l; 2 G/PEGþP¼120 and
129mmol/l), and none had any obvious clinical symptoms.
The subject who had a serum sodium level of 120mmol/l had
a baseline serum sodium level of 131mmol/l (drawn for
reasons unrelated to this study).
Two subjects, both with no known pre-existing renal
disease, had post-preparation serum potassium levels
o3.0mmol/l (1 G/PEGþP¼2.6mmol/l, 1 G/PEGþB¼
2.9mmol/l) and neither had any obvious clinical symptoms.
One subject with no known pre-existing renal disease
had a post-preparation serum creatinine Z1.50mg/dl (1 G/
PEGþB¼1.57mg/dl) and had no obvious clinical symptoms.
IntheNUarm,theBBPSforsubjectsconsuming33–75%of
their preparation was 7.27±1.81 (n¼31), for those consum-
ing 76–99% of their preparation was 8.13±1.56 (n¼32),
for those consuming 100% of their preparation was 7.93±
1.45 (n¼137, Po0.04 vs.33–75%), and forthoseconsuming
76–100% of their preparation was 7.97±1.48 (n¼168,
Po0.03 vs. 33–75%).
In all three arms combined, the BBPS for subjects
scheduled to undergo colonoscopy from 0800 to 0900h was
8.02±1.47 (n¼130), from 0915 to 1000h was 7.99±1.41
(n¼209), from 1015 to 1100h was 7.96±1.25 (n¼170), and
from 1115 to 1200h was 7.82±1.63 (n¼91, P¼0.34 vs.
0800 to 0900h).
The correlation coefﬁcient between the total BBPS and the
total OPS was  0.796.
In all three arms combined (when all three colon segments
were rated), inadequate preparations were found in 8 of
8 (100%) subjects with BBPS r3, 7 of 8 subjects (87.5%)
with BBPS¼4, 10 of 17 subjects (58.8%) with BBPS¼5,
1 of 64 subjects (1.6%; colon segments: right¼1, trans-
verse¼3, left¼2) with BBPS¼6, 1 of 70 subjects (1.4%;
colon segments: right¼1, transverse¼3, left¼3) with
BBPS¼7, and 0 of 425 subjects (0%) with BBPS Z8.
Preparation tolerance by subjects. The data from the
subject questionnaire for each arm is shown in Table 6.
Only three subjects (3 NU) could not consume more than
50% of their preparation and were switched to G/PEG. All
three were counted, on an intention-to-treat basis, in the NU
arm: two had BBPS¼9 and one had a BBPS¼3 and an
inadequate preparation.
DISCUSSION
Ourinvestigator-blindedstudyfoundnostatisticallysigniﬁcant
differences in the BBPS among the three preparation arms.
There was no statistically signiﬁcant difference between the
BBPS of the G/PEG arms combined, and the NU arm, or in
the OPS (a secondary endpoint of our study) among the
three arms. This is the ﬁrst randomized trial to show that
Gatorade/PEG can be as effective in cleansing the colon as
a 4-l PEG-ELS.
Only 27 subjects (4.5%) had colon preparations that were
rated as inadequate for a good quality colonoscopy by the
gastroenterologist. There was no statistically signiﬁcant
difference between the number of inadequate preparations
in the G/PEG arms combined and the NU arm. If the three
patients who were unable to tolerate the NuLYTELY were
included with the inadequate preparations, the difference
between the G/PEG arms combined and the NU arm would
remain not statistically signiﬁcant.
Subjects intheG/PEGþBarmhadastatistically signiﬁcant
increase in abdominal cramps/pain compared with those in
the G/PEGþP arm, but overall, did not ﬁnd the preparation
more difﬁcult. One previous investigator-blinded study
10 had
compared a 255-g version of G/PEG with and without 10mg
of bisacodyl, and found no signiﬁcant difference in the OPS
between the two arms (P-value not reported).
Table 4 Colon cleanliness data from the questionnaire ﬁlled out by the gastroenterologists immediately after the colonoscopy
1 NuLYTELY
or TriLyte
2 Gatorade/
PEG with
placebo
P-value
1 vs. 2
3 Gatorade/
PEG with
10mg bisacodyl
P-value
2 vs. 3
P-value
1 vs. 3
4 Gatorade/
PEG
(both arms)
P-value
1 vs. 4
BBPS
Right colon (mean±s.d.) 2.45±0.67 2.49±0.60 0.53 2.53±0.63 0.52 0.22 2.51±0.61 0.27
Transverse colon (mean±s.d.) 2.70±0.53 2.78±0.48 0.11 2.74±0.47 0.40 0.42 2.76±0.47 0.16
Left colon (mean±s.d.) 2.71±0.58 2.77±0.49 0.26 2.72±0.55 0.44 0.86 2.75±0.51 0.39
Total BBPS (mean±s.d.) 7.86±1.55 8.05±1.28 0.18 7.99±1.41 0.66 0.38 8.02±1.34 0.19
OPS
Right colon (mean±s.d.) 1.18±0.96 1.14±0.95 0.68 1.07±0.88 0.44 0.23 1.11±0.91 0.38
Transverse/descending colon
(mean±s.d.)
0.66±0.79 0.58±0.83 0.32 0.57±0.73 0.90 0.24 0.58±0.79 0.24
Sigmoid/rectum (mean±s.d.) 0.60±0.86 0.53±0.77 0.39 0.67±0.87 0.09 0.42 0.60±0.83 1.00
Fluid total colon (mean±s.d.) 0.35±0.55 0.32±0.49 0.56 0.39±0.59 0.20 0.48 0.36±0.54 0.83
Total OPS (mean±s.d.) 2.80±2.24 2.58±2.47 0.35 2.71±2.47 0.60 0.70 2.65±2.47 0.47
Inadequate preparation 11 7 0.33 9 0.61 0.65 16 0.40
Failed or inadequate Preparation 13 7 0.17 9 0.61 0.38 16 0.18
Abbreviations: BBPS, Boston Bowel Preparation Scale; OPS, Ottawa Preparation Scale.
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1
NuLYTELY
or TriLyte
2 Gatorade/
PEG with
placebo
P-value
1 vs. 2
3 Gatorade/
PEG with
10mg bisacodyl
P-value
2v s .3
P-value
1v s .3
4 Gatorade/
PEG (both
arms)
P-value
1 vs. 4
Subjects with no known renal disease (N) 191 193 0.61 195 0.56 0.28 388 0.35
Na (mmol/l) (mean±s.d.) 139.8±2.6 138.8±3.0 o0.0005 139.3±2.5 0.08 0.05 139.0±2.7 o0.0007
K (mmol/l) (mean±s.d.) 4.29±0.42 4.26±0.44 0.49 4.25±0.42 0.82 0.35 4.26±0.43 0.43
Cl (mmol/l) (mean±s.d.) 104.1±2.7 103.4±3.1 o0.02 103.4±2.9 1.00 o0.02 103.4±3.0 o0.007
CO2 (mmol/l) (mean±s.d.) 23.7±2.3 23.7±2.3 1.00 23.8±2.4 0.68 0.68 23.8±2.3 0.62
BUN (mg/dl) (mean±s.d.) 13.1±3.9 11.3±3.9 o0.0001 12.0±4.2 0.09 o0.008 11.6±4.0 o0.0001
Cre (mg/dl) (mean±s.d.) 0.95±0.18 0.94±0.19 0.60 0.94±0.18 1.00 0.59 0.94±0.19 0.54
Ca (mg/dl) (mean±s.d.) 9.38±0.40 9.54±0.48 o0.0004 9.50±0.46 0.40 o0.007 9.52±0.47 o0.0004
Na o130mmol/l 1 2 1.00 0 0.50 1.00 2 1.00
K o3.0mmol/l 0 1 1.00 1 1.00 1.00 2 0.55
3.0mmol/l rK o3.5mmol/l 5 3 0.72 4 1.00 1.00 7 0.76
Cre Z1.30mg/dl 4 6 0.75 6 1.00 0.75 12 0.60
Subjects with known Cre Z1.30 (N) 9 7 0.61 5 0.56 0.28 12 0.48
Change Na (mmol/l) (mean±s.d.)  2.0±3.0  0.7±3.3 0.42  2.0±3.7 0.54 1.00  1.2±3.4 0.58
Change K (mmol/l) (mean±s.d.)  0.6±1.8  0.10±0.54 0.49  0.26±0.31 0.56 0.69  0.17±0.45 0.43
Change Cl (mmol/l) (mean±s.d.)  0.8±2.3  0.3±1.7 0.64  1.8±2.8 0.27 0.48  0.9±2.2 0.92
Change CO2 (mmol/l) (mean±s.d.)  1.8±3.1  2.0±2.6 0.89  3.0±1.7 0.47 0.44  2.4±2.2 0.61
Change BUN (mg/dl) (mean±s.d.)  7.5±7.7  10.9±7.5 0.39  6.4±4.2 0.26 0.77  9.0±6.5 0.63
Change Cre (mg/dl) (mean±s.d.)  0.12±0.17  0.12±0.18 1.00  0.04±0.14 0.43 0.39  0.09±0.17 0.69
Change Ca (mg/dl) (mean±s.d.)  0.01±0.41 0.23±0.35 0.24 0.44±0.61 0.46 0.12 0.3±0.5 0.15
In subjects known to have a baseline creatinine Z1.30mg/dl, the data is shown as the change in electrolytes calculated from a baseline basic metabolic proﬁle drawn
before the bowel preparation and the basic metabolic proﬁle drawn before the intravenous line for the colonoscopy was started.
P-values in bold signify signiﬁcance levels o0.05.
Table 6 Data from the questionnaire ﬁlled out by the subjects immediately before their colonoscopy
1 NuLYTELY
or TriLyte
2 Gatorade/
PEG with
placebo
P-value
1 vs. 2
3 Gatorade/
PEG with
10mg
bisacodyl
P-value
2 vs. 3
P-value
1 vs. 3
4 Gatorade/
PEG
(both arms)
P-value
1 vs. 4
Side effects
Nausea (mean±s.d.) 0.64±0.86 0.41±0.72 o0.04 0.45±0.71 0.58 o0.02 0.43±0.72 o0.02
Vomiting (mean±s.d.) 0.22±0.64 0.06±0.34 o0.02 0.11±0.48 0.23 0.05 0.09±0.42 o0.03
Abdominal cramps/pain
(mean±s.d.)
0.46±0.70 0.31±0.56 o0.02 0.46±0.60 o0.01 1.00 0.39±0.59 0.20
Bloating (mean±s.d.) 0.96±0.85 0.74±0.71 o0.005 0.76±0.74 0.78 o0.02 0.75±0.72 o0.002
Other side effects
Headache 4 10 0.10 6 0.31 0.52 16 0.20
Other 13 7 0.17 9 0.61 0.38 16 0.18
% Preparation consumed (mean±s.d.) 93.4±12.9 98.9±5.3 o0.0001 99.3±3.9 0.39 o0.0001 99.1±4.6 o0.0001
Consumed 100% of Preparation 137 188 o0.0001 191 0.50 o0.0001 379 o0.0001
Incomplete % consumed (mean±s.d.) 79.0±14.9 82.3±13.6 0.48 82.6±10.2 0.96 0.49 82.4±12.0 0.35
Called MD for advice 8 16 0.09 10 0.22 0.63 26 0.21
Needed Fleets enemas 23 28 0.45 31 0.67 0.24 59 0.27
Number of enemas (mean±s.d.) 1.52±0.73 1.54±0.69 0.92 1.68±0.65 0.43 0.40 1.62±0.67 0.56
Changed preparation due to intolerance 3 0 0.25 0 1.00 0.25 0 o0.04
Woke up at night for bowel movement 104 127 o0.02 129 0.84 o0.02 256 o0.005
Would use the same preparation again 114 185 o0.0001 182 0.58 o0.0001 367 o0.0001
How difﬁcult was
Drink liquid (mean±s.d.) 1.33±0.97 0.41±0.62 o0.0001 0.45±0.70 0.55 o0.0001 0.43±0.66 o0.0001
Overall preparation (mean±s.d.) 0.97±0.96 0.38±0.63 o0.0001 0.42±0.67 0.54 o0.0001 0.40±0.65 o0.0001
Had previous colonoscopy 116 123 0.48 133 0.30 0.08 256 0.15
Previous preparation
Any 4-liter PEG preparation 10E:77S:9M 79E:16S:5M o0.0001 85E:15S:7M 0.84 o0.0001 164E:31S:12M o0.0001
Any sodium phosphate pills 3E:4S:4M 6E:4S:1M 0.27 4E:5S:4M 0.38 1.00 10E:9S:5M 0.53
Fleets phospho-soda 0E:1S:4M 1E:3S:3M 0.56 2E:0S:2M 0.18 0.29 3E:3S:5M 0.62
Any 2-liter Gatorade/PEG 0E:1S:2M 0E:1S:1M 1.00 1E:6S:2M 0.62 0.62 1E:7S:3M 0.62
Abbreviations: PEG, polyethylene glycol; E, easier, S, same; M, more difﬁcult.
For ‘‘previous preparation,’’ the study preparation was E, S, M, compared with the previous preparation.
P-values in bold signify signiﬁcance levels o0.05.
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13 of 45 subjects compared the colon cleanliness
after a 4-liter PEG-ELS solution with and without 10mg of
bisacodyl, and concluded that there was no signiﬁcant
difference between the arms. A study
14 with 442 subjects
compared versions of HalfLytely (2 lSF-PEG-ELS) with 10
and 20mg of bisacodyl and found no difference in colon
cleanliness, but fewer side effects were seen with the 10-mg
version. An unpublished study with 308 subjects described in
the HalfLytely package insert compared versions of the
HalfLytely with 5 and 10mg of bisacodyl, and found no
difference in colon cleanliness. There are no published
studies that show that bisacodyl is effective as part of a
modern colon-cleansing preparation.
4
Using low-ELS, such as Gatorade, as part of a preparation
forcolonoscopycouldcauserenal injuryorelectrolyteshiftsto
occur from the large quantity of PEG and water consumed.
Subjects with no known pre-existing renal disease in both
G/PEG arms combined had statistically signiﬁcant lower
serum sodium, lower serum chloride, lower serum BUN, and
higher serum calcium levels compared with similar subjects
in the NU arm. No signiﬁcant differences in the serum
creatinine or potassium levels were noted among the three
preparation arms. Although the electrolyte differences were
statistically signiﬁcant, the absolute differences between
arms were small and not associated with any clinical
symptoms. The two previous studies
9,10 comparing G/PEG
preparations with GoLYTELY did not measure the subject’s
serum chemistries.
As baseline BMPs were not drawn in subjects with no
known pre-existing renal disease, it is impossible to know
how much their serum chemistries changed. Previous
studies
5,15,16 with NuLYTELY found small and inconsistent
changes in serum chemistries after a preparation with
NuLYTELY.Inthisstudy,thedifferencesinserumchemistries
between subjects in the NU arm and G/PEG arms combined
were small, suggesting that the changes in serum chemistries
after a G/PEG preparation were also small.
There is a case report
17 of a 73-year-old woman who
developed a seizure and was found to have a serum sodium
level of 117mmol/l following a preparation with 64oz of
Gatorade and 255g of PEG. An abstract
18 reported 14
patients with severe hyponatremia, following preparations
with G/PEG. Our G/PEG has not been widely used, and
studies with large numbers of subjects using this preparation
would be reassuring.
In the 21 subjects with a baseline creatinine Z1.30mg/dl,
who had both a baseline and pre-colonoscopy BMP
drawn, no signiﬁcant changes in serum chemistries were
noted among the three preparation arms. The number
of subjects with pre-existing renal disease was small
and no subject with a creatinine 42.45mg/dl enrolled in our
study.
Subjects in the G/PEG arms tolerated their preparations
far better than subjects in the NU arm by almost every
measureusedinthis study.Comparedwithsubjects inthe NU
arm, subjects in the G/PEGþP arm had statistically
signiﬁcantly less nausea, vomiting, abdominal cramps/pain,
and bloating. Compared with subjects in the NU arm, subjects
in both G/PEG arms combined had statistically signi-
ﬁcantly less difﬁculty drinking the liquid, found the overall
preparation easier to tolerate, were able to consume 100%
of the preparation more frequently, and were more willing
to use the same preparation again for a future colonoscopy.
Of the subjects who had used any 4-liter PEG preparation
for their previous colonoscopy, more subjects found the
preparations in the G/PEG arms combined easier to consume
than the preparation in the NU arm. These ﬁndings were not
only statistically signiﬁcant, but in absolute terms, the
differences were quite large. These ﬁndings are clinically
important, as the consumption of the bowel preparation is
the most commonly cited reason for not undergoing a
colonoscopy.
2
Compared with subjects in the NU arm, subjects in both
G/PEG arms combined more frequently woke up at night to
have a bowel movement.
Our 306g version of G/PEG used a non-traditional split
dose with 51g of PEG at noon the day before the
colonoscopy, which may have reduced the side effects
compared with NuLYTELY, and accounted for the superior
cleansing results compared with other trials
9,10 with G/PEG.
Our G/PEG had 51 to 68g more PEG compared with
other G/PEG studies,
9,10 which might have cleansed
the colon better. The Fleets enemas given to subjects
whose stools were not clear on the morning of the colono-
scopy may have salvaged some preparations, which other-
wise would have been inadequate. SF-PEG ELS
(NuLYTELY) is better tolerated than sulfate-containing solu-
tions,
4 such as GoLYTELY, making our ﬁndings even more
clinically relevant.
The American College of Gastroenterology recommends
19
that bowel preparations be given as PM/AM split doses. Two
studies
20,21 have compared the day before dosing of a 4-liter
PEG-ELS preparation with the PM/AM split dosing of a similar
preparation and found the split-dosing regimens produced
signiﬁcant better bowel preparations. The day before regi-
mens produced good or excellent results in 39.4–56.2%
of subjects, whereas the split-dosing regimens produced
good or excellent results in 76.5–94.4%. In both studies,
(1) subjects in the day before arms consumed a liquid diet the
day before the colonoscopy; (2) subjects in the split-dosing
arms consumed a regular diet the day before the colono-
scopy; and (3) the 4-liter PEG-ELS preparations contained
sodium sulfate.
All three arms of our study used day before dosing and
had adequate preparations in 94.5–96.5% of subjects. These
excellent results may have been because of the use of a
sulfate-free 4-liter PEG lavage (NuLytely), the clear liquid diet
given to our subjects the day before the procedure, or the
Fleets enemas given to subjects whose stools were not clear
on the morning of the colonoscopy.
If colonoscopy preparations are sufﬁciently well tolerated
and efﬁcacious, split dosing may be unnecessary for morning
procedures. Only head-to-head comparisons in randomized
trials of these different bowel preparations will deﬁnitively
answer these questions.
In our study, 94.7% of subjects in the G/PEG arms
combined were able to ﬁnish their preparations compared
with68.5%ofsubjectsintheNUarm,buttheseﬁndingsdonot
explain why the colons were as clean in the G/PEG arms
as they were in the NU arm. Subjects in the NU arm
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prescribed amount) compared with 303g (99.1% of
the prescribed amount) in both G/PEG arms combined. The
31 subjects (15.5%) who consumed 139–315g of PEG in
their NuLYTELY (33–75% of the prescribed amount) had a
signiﬁcantly lower average BBPS compared with that of the
169 subjects (84.5%) who consumed 319–420g of PEG in
their NuLYTELY (76–100% of the prescribed amount). If the
31 subjects who consumed 33–75% of their NuLYTELY were
excluded from the NU arm, the BBPS of the remaining 169
subjects would be very similar to the BBPS for the 400
subjects in both G/PEG arms combined. This is further
evidencethat238–255gofPEGmaynotbeenoughtoreliably
lavage the colon.
Five studies
15,22–25 have compared various 2-liter
PEG-ELS solutions with 15–20mg of bisacodyl to similar 4-
liter PEG-ELS solutions without bisacodyl and concluded
that there was no signiﬁcant difference in cleanliness
between the arms, and that the 2-liter preparations were
better tolerated. None of these studies used both the SF-
PEG-ELS and a sensitive and validated measure of colon
cleanliness.
It has been reported that the quality of colonoscopy
preparations declines as the time between the preparation
and colonoscopy increases.
26 We found no signiﬁcant
difference between the BBPS of colonoscopies performed
between 0800 and 0900h compared with 1115 and 1200h. It
should be noted that by design in this study, no afternoon
procedures were studied.
This is the ﬁrst study to use both the BBPS and the OPS
to rate colon cleanliness. The colon segments rated on
the BBPS (right, transverse, and left) were easier for the
gastroenterologist to deﬁne during colonoscopy than those
rated on the OPS (right, transverse/descending, and sigmoid/
rectum). The BBPS rated each segment after washing and
suctioning, whereas the OPS rated each segment before
cleaning was attempted. The BBPS was more clinically
relevant, because the visualization of the mucosa is the
primary goal of any bowel preparation. The OPS was more
sensitive to truly outstanding colon preparations, as it
distinguished between segments that required no cleaning
and those that required some cleaning. Despite these
differences, the results on the BBPS and OPS were
moderately-to-strongly correlated (r¼ 0.796).
Both the BBPS and OPS suffer from poorly designed
scoring systems that are not easily converted into the poor/
fair/good/excellent subjective rating scale, which is often
used by gastroenterologists in their colonoscopy reports.
A colon with minor residual material throughout the colon
would receive a BBPS¼6, and most gastroenterologists
would consider this a good preparation. A colon with a
clean transverse and left colon, but with stool that could
not be cleared throughout the right colon, would receive the
same BBPS¼6, but the preparation would be poor.
A segment of colon is rated 1 on the BBPS, when a portion
ofmucosa ina segmentis seenafter cleaning, but other areas
are not seen due to retained material. The BBPS does not
specify the percentage of a segment’s mucosa that must not
be seen for it to be rated 1. Our adequate/inadequate scale
required at least 95% of the mucosa of the whole colon to be
well visualized for the preparation to be rated as adequate. It
was possible for a segment of the colon to be rated 1 on the
BBPS,yetthepreparationofthewholecolonontheadequate/
inadequate scale to be rated as adequate. An improved scale
to rate bowel cleanliness is needed to overcome these
limitations.
This study is being reported as an investigator-blinded
study of G/PEGþP vs. G/PEGþB rather than a double-
blinded study, because the placebo (folic acid) pills and
bisacodyl pills looked very similar, but were not identical.
To the best of our knowledge, patients did not know which
pill they were consuming.
In conclusion, we found the NU arm and both G/PEG arms
produced statistically similar colon cleansing when consumed
thedaybeforeamorningcolonoscopy.Subjects intheG/PEG
arms tolerated their preparations far better than those in the
NU arm. G/PEG appears to be as safe as NU with small
but statistically signiﬁcant electrolyte differences among
the arms, causing no clinical symptoms. G/PEG costs
about 25% as much as commercially available low-volume
colon-cleansing preparations, such as HalfLytely, MoviPrep,
VISICOL tablets, and SUPREP (see Table 1). Although a
formal cost effectiveness analysis was not performed,
using the G/PEG preparation described here could result in
a very signiﬁcant cost savings. In our practice, the G/PEG
(without bisacodyl) is used for most colon cleansings for
colonoscopy.
Adding 10mg of bisacodyl to G/PEG and 64oz of Gatorade
for colon lavage caused more abdominal bloating/cramps,
and did not result in a cleaner colon. There is no evidence that
bisacodyl is effective as part of a PEG colon-cleansing
preparation and its widespread use as part of various colon-
lavage preparations needs to be re-examined.
Future studies need to determine: (1) if the G/PEG used in
thisstudyprovidestheoptimalbalanceofcoloncleansingwith
patient safety and tolerance; (2) if any clear liquid could be
substituted for Gatorade; (3) how the G/PEG preparation
compares with other commercially available preparations; (4)
the safety of the G/PEG preparation in larger numbers of
patients,includingthosewithrenalinsufﬁciencyandCHF;and
(5) if the inconvenience of a PM/AM split-dose G/PEG
preparation is outweighed by the improved cleanliness for
morning colonoscopies.
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WHAT IS CURRENT KNOWLEDGE
| Concern about the bowel preparation is the most
common reason people do not have a colonoscopy.
| Low compliance with bowel preparations can result
in suboptimal colon visualization.
| Preparations with Gatorade and PEG (up to 255g)
are not as efﬁcacious as 4-liter electrolyte–PEG
solutions.
| The safety of Gatorade and PEG preparations has
not been assessed in a trail using BMPs.
| Bisacodyl has not been shown to be effective as part
of a modern colon-cleansing preparation.
WHAT IS NEW HERE
| A new preparation using 64oz of Gatorade and
G/PEG is described.
| Adding bisacodyl to Gatorade/PEG caused more
side effects and did not result in a cleaner colon.
| Gatorade/PEG (306g version) and NuLYTELY are
equally efﬁcacious when given the evening before
a morning colonoscopy.
| Gatorade/PEG (306g version) was far better
tolerated than NuLYTELY
| Gatorade/PEG resulted in lower serum sodium, chloride,
and BUN levels than NuLYTELY, but these
differences were small and not clinically important.
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